重组人促红素联合蔗糖铁对糖尿病肾病血液透析患者贫血状态及CysC、CRP的改善作用研究  

Effect of recombinant human erythropoietin combined with sucrose iron on anemia status and CysC,CRP levels in hemodialysis patients with diabetes nephropathy

作　　者：张金凤 刘巧梅 马世昌 Zhang Jin-feng;Liu Qiao-mei;Ma Shi-chang(Department of Nephrology,Shangqiu Hospital of Traditional Chinese Medicine,Shangqiu 476000,Henan,China)

机构地区：[1]商丘市中医院肾病科,河南商丘476000

出　　处：《四川生理科学杂志》2024年第1期140-143,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:分析重组人促红素联合蔗糖铁对糖尿病肾病(Diabetic nephropathy,DN)血液透析患者的治疗效果。方法:选取2020年3月至2022年3月我院诊治的98例DN血液透析患者,随机分为对照组、观察组,各49例。对照组给予重组人促红素,观察组给予重组人促红素+蔗糖铁。对比两组临床疗效、贫血状态、炎症状态、肾功能及不良反应情况。结果:观察组总有效率较对照组高(P<0.05);治疗后观察组各贫血状态指标均高于对照组,各炎症状态和肾功能指标均低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义。结论:重组人促红素联合蔗糖铁可改善DN血液透析患者贫血状态、肾功能,并缓解炎症状态。Objective:To analyze the therapeutic effect of recombinant human erythropoietin combined with sucrose iron on hemodialysis patients with diabetes nephropathy(DN).Methods:98 cases of DN hemodialysis patients treated in our hospital from March 2020 to March 2022 were randomly divided into control group and observation group with 49 cases in each group.The control group was given recombinant human erythropoietin,and the observation group was given recombinant human erythropoietin and sucrose iron.The clinical efficacy,anemia status,inflammatory status,renal function and adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was higher than that in the control group(P<0.05);After treatment,the levels of anemia status indexes in the observation group were higher than those in the control group,the levels of inflammatory status and renal function were lower than those in the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Recombinant human erythropoietin combined with sucrose iron can improve anemia status and renal function,and alleviate inflammation in DN hemodialysis patients.

关 键 词：重组人促红素 蔗糖铁 糖尿病肾病 血液透析 贫血 

分 类 号：R587.2[医药卫生—内分泌] R692[医药卫生—内科学]